ABBV vs BMY Stock Comparison: AI Score, Valuation, Performance and Upside
AbbVie and Bristol-Myers Squibb are both large-cap biopharma companies navigating major revenue transitions, but AbbVie's Humira replacement (Skyrizi and Rinvoq) is more advanced and de-risked than BMY's Revlimid transition. ABBV's transition is largely on track; BMY's is earlier-stage and more uncertain. Both offer high dividend yields, but ABBV's dividend sustainability looks better supported by its near-term pipeline.
Both stocks are deep value biopharma plays with high dividends and near-term revenue headwinds, but AbbVie's transition is more proven — investors should assess which company's pipeline provides the stronger bridge to a post-transition growth phase.
ABBV holds the edge across 3 of 5 key metrics in this comparison. BMY leads on both 1-year return (+38.29%) and forward P/E quality (10.15x vs 15.79x for ABBV), a relatively favorable combination of momentum and valuation. ABBV leads on both revenue growth (10.20%) and operating margin (40.03%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABBV (+7.85%) than for BMY (-0.56%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- want high dividend yield from a biopharma company with a visible post-Humira transition path
- value Skyrizi and Rinvoq's proven revenue growth as a de-risked successor franchise
- prefer immunology and aesthetics exposure over oncology
- are comfortable with moderate leverage from the Allergan acquisition
- seek deep-value biopharma with a high dividend and potential recovery from a loss-of-exclusivity trough
- believe Cobenfy (schizophrenia) and radiopharmaceuticals represent underappreciated pipeline value
- want oncology exposure through Opdivo across 15+ tumor types
- are comfortable with more pipeline uncertainty in exchange for a lower entry valuation
| Metric | ABBV | BMY |
|---|---|---|
| AI scorei | 53.2 | 40.5 |
| AI ranki | #353 | #1136 |
| Latest closei | $263.96 | $63.06 |
| 1M returni | -0.76% | -6.73% |
| 6M returni | +27.99% | +8.52% |
| 1Y returni | +18.91% | +38.29% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | BMY |
|---|---|---|
| 1Y ago | $11.89K (+18.9%) started 2025-09-18 | $13.83K (+38.3%) started 2025-09-18 |
| 5Y ago | $33.47K (+234.7%) started 2021-09-20 | $14.07K (+40.7%) started 2021-09-20 |
| 10Y ago | $95.09K (+850.9%) started 2016-09-19 | $21.53K (+115.3%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | BMY |
|---|---|---|
| Market capi | $454.36B | $136B |
| Trailing P/Ei | 72.43 | 14.67 |
| Forward P/Ei | 15.79 | 10.15 |
| Price/Salesi | 5.85 | 2.07 |
| EV/Revenuei | 8.06 | 3.46 |
| Analyst targeti | $277.31 | $66.21 |
| Target upsidei | +7.85% | -0.56% |
| Metric | ABBV | BMY |
|---|---|---|
| Revenue growthi | 10.20% | 5.70% |
| Earnings growthi | 290.40% | 153.10% |
| EPS growthi | +290.40% | +153.10% |
| FCF margini | +26.20% | +16.50% |
| Operating margini | 40.03% | 34.42% |
| Profit margini | 9.80% | 18.87% |
| ROIC proxyi | 6225.00% | 46.60% |
| Return on equityi | 6225.00% | 46.60% |
| Dividend yieldi | 2.69% | 3.76% |
| Payout ratioi | 190.40% | 55.29% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.28 | 0.23 |
| Debt/equityi | 4789.60 | 201.86 |
| Current ratioi | 0.81 | 1.53 |
| Quick ratioi | 0.49 | 1.29 |
Over the past year, ABBV and BMY have moved moderately in the same direction (correlation of 0.52), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | BMY |
|---|---|---|---|
| 1Y | Growthi | +18.91% | +38.29% |
| CAGRi | +18.92% | +38.32% | |
| Volatilityi | 26.43% | 27.50% | |
| Sharpe ratioi | 0.62 | 1.16 | |
| Sortino ratioi | 0.94 | 1.85 | |
| Max drawdowni | 19.23% | 13.42% | |
| Current drawdowni | 0.76% | 7.39% | |
| Avg drawdowni | 7.66% | 4.34% | |
| Ulcer Indexi | 9.00% | 5.49% | |
| Max daily dropi | 5.20% | 4.07% | |
| Max wkly dropi | 8.49% | 7.58% | |
| 5Y | Growthi | +186.61% | +20.47% |
| CAGRi | +23.47% | +3.80% | |
| Volatilityi | 23.37% | 24.64% | |
| Sharpe ratioi | 0.83 | 0.09 | |
| Sortino ratioi | 1.16 | 0.13 | |
| Max drawdowni | 21.92% | 47.67% | |
| Current drawdowni | 0.76% | 13.57% | |
| Avg drawdowni | 8.02% | 21.01% | |
| Ulcer Indexi | 9.97% | 24.82% | |
| Max daily dropi | 12.57% | 8.51% | |
| Max wkly dropi | 17.30% | 11.78% | |
| 10Y | Growthi | +508.23% | +53.36% |
| CAGRi | +19.79% | +4.37% | |
| Volatilityi | 26.02% | 24.95% | |
| Sharpe ratioi | 0.65 | 0.12 | |
| Sortino ratioi | 0.91 | 0.16 | |
| Max drawdowni | 45.09% | 47.67% | |
| Current drawdowni | 0.76% | 13.57% | |
| Avg drawdowni | 11.54% | 16.68% | |
| Ulcer Indexi | 15.57% | 20.66% | |
| Max daily dropi | 16.25% | 13.26% | |
| Max wkly dropi | 19.39% | 17.10% |
| Category | ABBV | BMY |
|---|---|---|
| Company | AbbVie Inc. | Bristol-Myers Squibb Company |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | AbbVie is a research-based biopharmaceutical company best known for Humira, historically the world's best-selling drug, which now faces biosimilar competition. AbbVie is executing a successful transition to Skyrizi (IL-23 inhibitor) and Rinvoq (JAK inhibitor) in immunology, which are growing rapidly and expected to surpass Humira's peak revenue. The Allergan acquisition added Botox, aesthetics, and neuroscience assets diversifying beyond immunology. | Bristol-Myers Squibb is a global biopharmaceutical company with major franchises in oncology (Opdivo/Yervoy immuno-oncology, Revlimid), cardiovascular (Eliquis co-commercialized with Pfizer), and hematology. The company faces a simultaneous 'loss of exclusivity' cliff from Revlimid and Opdivo over 2025-2028, which it is attempting to offset with recent acquisitions including Karuna (neuroscience) and RayzeBio (radiopharmaceuticals). The Revlimid transition is the defining challenge. |
| Investor focus | Investors track the Skyrizi and Rinvoq combined revenue trajectory (the key transition metric), Botox aesthetic demand, the oncology and neuroscience pipeline depth, and dividend sustainability given the post-Humira revenue transition. | Investors track the Revlimid loss of exclusivity impact on revenues, new product launches (Breyanzi, Camzyos, Sotyktu), the Karuna/Cobenfy launch for schizophrenia, and whether the diversified pipeline can compensate for the revenue cliff fast enough. |
- Skyrizi and Rinvoq combined growing 50%+ and on track to exceed Humira peak revenue
- Allergan acquisition added Botox aesthetics creating a differentiated non-cyclical revenue stream
- Consistent dividend growth history with commitment to shareholder returns
- Opdivo immuno-oncology platform approved across 15+ tumor types with ongoing label expansions
- Eliquis (co-promoted with Pfizer) is the world's top-selling oral anticoagulant
- Karuna acquisition adds Cobenfy, a first-in-class schizophrenia treatment with potential blockbuster status
- Humira biosimilar erosion is faster than some forecasts, creating near-term revenue headwinds
- Heavy debt from the Allergan acquisition limits balance sheet flexibility
- Rinvoq faces FDA safety label restrictions limiting its addressable market
- Revlimid loss of exclusivity creates a multi-billion dollar revenue cliff
- Heavy M&A debt load reducing financial flexibility
- Opdivo checkpoint inhibitor market becoming increasingly crowded
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.